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Sunlnlal~ 
We have analyzed the nucleotide sequences of 19 e V.5 transcripts  derived from in vivo isotype 
switched peripheral blood B cells of three patients  with atopic dermatitis.  Comparison with 
the patients' own germline V.5 gene segments revealed that the e transcripts were derived from 
both  functional members of the human V.5  gene family  and harbored numerous somatic 
mutations (range 5-36 per V.5 gene). In two patients, we detected clonally related but diverged 
transcripts,  permitting the construction of a genealogical tree in one patient. We observed a 
high proportion of shared silent (S) and replacement  (R) mutations among e V.5 sequences 
derived from all three individuals,  even among transcripts  descending from the two different 
germline V.5 gene segments.  A remarkably high number of these mutations is shared with 
previously  reported V~5 genes  encoding antibodies  with defined  specificities. The  shared S 
mutations, and likely a fraction of the R mutations, appear to mark preferential sites ("hot spots") 
of somatic hypermutations in human V.5 genes. The distribution of R  and S mutations over 
complementarity determining region and framework regions  in the majority of V. regions 
deviated from that characteristic of antigen-driven immune response. We hypothesize that the 
V regions of immunoglobulin E-bearing B cells have accumulated "selectively neutral" mutations 
over extended periods  of clonal expansion,  resulting in unusual R/S ratios.  We propose  that 
the molecular characteristics of the e V. regions in atopic dermatitis may be representative of 
antigens that recurrently or chronically  stimulate  the immune system. 
opic dermatitis is an inflammatory skin disorder charac- 
terized by a chronically relapsing course with frequent 
exacerbations and a distinctive clinical morphology. Although 
the primary cause of atopic dermatitis is unknown, substan- 
tial evidence suggests that excessive production of IgE anti- 
bodies likely contributes to the pathogenesis of this disorder 
(1, 2). These antibodies  are reactive with a wide variety of 
environmental allergens. The regulatory effects of allergen- 
reactive T lymphocytes and their lymphokine products ap- 
pear to be a major cause of the high serum levels of IgE in 
patients with atopic dermatitis (3-5). 
Although the role of alhrgen-reactive T cells in control- 
ling IgE class switching is beginning to be elucidated, little 
is known about the B lymphocytes that are recruited into 
the IgE response. In particular,  questions  related to the Ig 
gene segments encoding the V regions of IgE antibodies and 
the role of somatic hypermutation in the donal evolution 
of IgE responses have not been addressed. Similar studies on 
the molecular origin of human (anto)antibodies have largely 
depended on hybridoma technology and EBV transforma- 
tion to generate monoclonal B cell lines secreting relevant 
specificities. Attempts to immortalize B lymphocytes switched 
to IgE in vivo have generally been unsuccessful. 
In the present study we have employed a cDNA/PCR ap- 
proach to analyze the molecular structure of V regions ex- 
pressed in IgE antibodies of atopic dermatitis patients.  This 
strategy permitted the selective amplification of e V. region 
transcripts from RNA extracted from PBMC. Our data show 
that members of the V.3-V.6 gene families may be utilized 
in IgE antibodies from patients with atopic dermatitis.  The 
small  human V.5  gene family, which contains  only two 
functional members, was abundantly expressed in e transcripts. 
Comparison of the nucleotide sequences of 19 e V.5 tran- 
scripts  with the germline V.5 genes of these patients  re- 
vealed the accumulation of high numbers of somatic muta- 
tions.  A  surprisingly  high proportion  of silent  (S)  1 and 
1 Abbreviations  used in thispaper: FR., framework; R, rephcement mutation; 
S, silent mutation. 
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rived from different members of the V~5 gene family, In two 
patients,  we detected evidence for transcripts  derived from 
clonally related but diverged IgE-bearing B cells which, in 
one patient, permitted the construction of a genealogical tree. 
The results of these experiments are discussed in the context 
of the molecular mechanisms contributing to a dinicaUy rele- 
vant  IgE-mediated  chronic immune  response. 
Materials  and Methods 
Patients.  All patients analyzed suffered from severe atopic der- 
matitis according to the diagnostic criteria formulated by Hanifin 
et al. (6). Patient Pl is a female adult with a total serum IgE level 
of 18  x  103 kU/liter. Patient P2 is a 12-yr-old boy with a total 
serum IgE level of 5.3  x  103 kU/liter, and patient  P3 is a 9-yr- 
old boy with an IgE serum level of 9.9  x  103 KU/liter. IgE in 
the serum of all three patients reacted with more than 15 different 
environmental allergens as detected in Radio Allergosorbent  Test 
(RAST). 
DNA and RNA Isolation.  PBMC from atopic dermatitis  pa- 
tients were isolated by Ficoll-Hypaque density gradient centrifu- 
gation. Total cellular RNA was prepared from 2  x  10  e PBMC 
using RNAzoF  M  (Cinna/biotecx,  Friendwood,  TX) as described 
previously (7). EBV-transformed polyclonal B cell lines were gener- 
ated from 5  x  106 PBMC, and genomic DNA was isolated from 
106 EBV-transfurmed B cells as detailed elsewhere (8). 
First-strand  eDNA Synthesis and PCR.  Total  RNA was used as 
a template for first-strand cDNA with an oligoprimer specific for 
the first exon of the e constant  region  (Ce,  5'-TGTCCCGTT- 
GAGGGAG CCTGT-3')  and 10 U  of avian myeloblastosis virus 
(AMV)  reverse transcriptase  (Pharmacia, Uppsala,  Sweden), ac- 
cording to standard procedures (7). One tenth of the cDNA reac- 
tion mixture was amplified in a PCR employing a previously de- 
scribed set of 5' primers  specific for the human V.3, V,4, V,5, 
and V~6 gene families (9), in combination  with a second, nested 
3' Ce-specific primer  containing  a SalI restriction  site (5'-GGG- 
TCGACAGTCACGGAGGTGGCATT-3').  Genomic  DNA  was 
amplified with the 5' V~5-specific primer  and a 3' primer  100% 
homologous to sequences  in the 3' flanking region of  both functional 
VH5 genes (5'-GGGTCGACGGC~TC~TGG  T-3 (10). All 
PCR reaction mixtures contained 200 ng of each primer and 2.5 U 
Taq polymerase (Promega Biotec, Madison, WI). Amplifications 
were performed in a Bioexcellence  thermal cycler (Biores., Woerden, 
The Netherlands) and consisted of 35 cycles of 1 min denaturation 
at 94~  1.5 rain primer annealing at 65~  and 1.5 rain extension 
at 72~  After the last cycle, reaction mixtures were incubated for 
10 min at 72~  to ensure complete extension of all products. 
Cloning and Sequencing of PCR-amplified Material.  PCR-am- 
plified material was digested with restriction enzymes EcoRI and 
SalI (Pharmacia) and separated on a 0.8% low-malting agarose gel 
(Nusieve; FML Bioproducts, Rockland, ME). A fragment of ~450 
bp was excised and ligated into Bluescript (Stratagene Inc., La Jolla, 
CA) using standard procedures (7). After transformation  of com- 
petent D~5c, cells, colonies were transferred to nitrocellulose and 
screened with a 32P-labeled V~5 probe (11). DNA sequence anal- 
),sis was according to Sanger et al. (12) using the T7 sequencing 
kit (Pharmacia). 
Results 
II. Gene Famil2/ Utilization  in e  V.5 Transcripts.from Atopic 
Dermat/tis Pat/ents,  Total RNA extracted from PBMC of three 
patients with atopic dermatitis was extended with a Ce-specific 
primer and AMV reverse transcriptase,  and first-strand cDNA 
was amplified by PCR using a nested Ce-specific primer in 
combination  with  5'  primers  specific  for  the  human 
VH3--VH6 gene families. All four V. primers yielded amplified 
PCR products of the expected size.  The identity of PCR 
products was confirmed by hybridizing  Southern blots of 
amplified material with 32p-labded V. gene family-specific 
probes, indicating  the VH gene family specificity of all V~ 
primers used. The results demonstrated that e transcripts en- 
coded by members  of the  human  V.3-V.5  gene  families 
were present  in  three  atopic  dermatitis  patients,  whereas 
V.6-encoded  e  transcripts  were found in  patient  P3 only 
(data not  shown).  We were unable to  amplify e V. tran- 
scripts from PBMC of four nonatopic,  healthy donors. 
Molecular Analysis of Germline  V.5 Gene in Atopic Derma- 
titis Patients.  In all three patients, we obtained abundant PCR 
products  with  the  V.5  gene  family-specific  primer.  The 
human  V.5  gene  family  consists  of only  two  functional 
members both of which are extremely well-conserved in the 
human population (10). We focused on this gene family to 
analyze the molecular structure  of e VH5 gene transcripts. 
To that  end,  we first determined  the nudeotide  sequences 
of V.5  genes  present  in  the  germline  of these  patients. 
Genomic DNA from polyclonal, EBV-transformed B lines 
was used as starting material in PCR reactions employing 
primers specific for the leader and 3' end flanking sequences 
of both functional V.5 genes. For each patient, a minimum 
of 10 bacterial colonies hybridizing to a V.5 probe were ran- 
domly picked and used for nucleotide sequencing. In the ge- 
nome of each patient,  the two functional members of the 
V.5  gene  family  were  detected,  and  no  other  V.  family 
members or fragments were detected in this sequence anal- 
ysis. In patients Pl and P2, both members displayed 100% 
sequence identity to the published germline genes (represented 
by the sequences of the V.5-1R1  and V.5-2R1  rearrange- 
ments [11]).  In patient P3, we detected a single nudeotide 
difference in one of the V.5-1R1 alleles  (see legend to Fig. 
I).  Based on the large number of germline  V.5  genes se- 
quenced, we estimate the PCR-induced error frequency to 
be <1/1200  in 35 cycles. 
Inter-  and  Intraclonal  Somatic  Mutations  in  e  V.5  Tran- 
scripts.  To  investigate  the  molecular  structure  of e  V.5 
regions, first-strand cDNA was synthesized from total RNA 
of PBMC and subsequently amplified in the PCR using a 
Ce  and  VHS-specific primer  pair.  PCR-amplified  material 
was cloned into Bluescript vector and after transformation, 
multiple VHS-hybridizing colonies were used for nucleotide 
sequence analysis. AU 19 nudeotide sequences contained open 
reading  frames  and  were derived  from  e  V.5  transcripts, 
confirming  the  specificity of the  Ce  and V.5  primers.  In 
Figs. 1 and 2, we have compared the nucleotide and deduced 
amino  acid  sequences of the  expressed  and  germline  V.5 
genes of patients  Pl,  P2,  and P3.  Table  1 summarizes  the 
distribution of R and S mutations over framework and CDR 
regions. In this analysis, we excluded somatic mutations oc- 
curling in the junctional region, because the patient's germ- 
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available  for comparison. 
cDNA  clones VHP2-57 and VHP1-58 derive from  the 
germline V.5-2R1 gene,  whereas the other 17 cDNA clones 
descend from  the  germline  V,5-1R1  gene.  All  e  V,5  se- 
quences contain  somatic mutations,  ranging  from 6 to 37 
in the V, portion of individual transcripts.  Close inspection 
of sequences from patient P2 reveals that nudeotide sequences 
P2-51, P2-52, P2-53,  and P2-54 are not identical (between 
95.7 and 99.2%  sequence homology) but utilize the same 
D, and J.  gene segments  and  are indistinguishable  at  the 
V~/D. and D,/JHjunctions (Fig. 1). This strongly suggests 
that  the corresponding  B  cell clones are the progeny of a 
common precursor (13). By the same criteria, the collection 
of eight sequences from patient P1 contains two donally related 
IgE transcripts,  P1-54 and P1-57, that differ by four nucleo- 
tides in the V,  segment  (Fig.  1). 
Comparison of the nudeotide sequences of all e V.5 tran- 
scripts revealed that numerous mutations are shared among 
clonally related and unrelated sequences within one individual 
and among individuals.  These shared mutations are present 
in both CDR and framework (FR) regions and are silent 
or result in amino acid replacements.  Among the most ex- 
treme examples are mutations  that  occur in multiple inde- 
pendent e transcripts derived from all three donors (e.g., com- 
pare the C-~T  substitution  at position  173,  the G-~A at 
position 230,  and the C~T  substitution at position  180). 
It is notable that these mutations involve descendants from 
both the V.5-1R1  and V.5-2R1  germline  gene segments. 
Based on the four donally related e V.5 sequences from 
patient P2, we constructed a genealogical tree that shows the 
nature and reconstructs the likely order of somatic mutations 
that occurred during expansion of this B cell clone (Fig. 3). 
The tree has been constructed to require the lowest number 
of parallel  mutations.  A  total of 14 mutations  (six R  and 
seven S mutations)  is shared by all four sequences.  At the 
first branchpoint, four mutations are shared by clones P2-52 
and P2-53 (three R  and one S mutation). These clones differ 
from each other by four R  and one S mutation.  Similarly, 
clone P2-54 and P2-51 share four R  and two S mutations 
and differ from each other by one S and one R  mutation. 
19, and.[, Gene Utilization.  All J~ gene segments except 
J.2 were present in the e transcripts.  The D.-gene segments 
were defined as the nudeotide  sequences between the V.- 
and Jwgenes, and include putative N  insertions. The D. seg- 
ments varied extensively in nucleotide sequence and length 
and displayed partial sequence homology with previously pub- 
lished germline  or expressed D. elements  (Fig.  4). 
Discussion 
Antibody diversity is generated through a number of mech- 
anisms including somatic assembly and imprecise joining of 
multiple gene segments, combinatory assortment of different 
Ig H  and L chains,  and somatic hypermutation.  Although 
the genetic mechanisms of antibody diversity are fairly wdl 
understood, little is known about their contribution to the 
human antibody response to clinically relevant exogenous an- 
tigens. We have analyzed Ig e VH gene transcripts from pe- 
ripheral blood B cells of three patients with atopic derma- 
titis. The sera of these patients contained IgE antibodies reactive 
with at least 15 different environmental allergens.  Our ina- 
bility to amplify e transcripts from peripheral blood B cells 
of nonatopic individuals  strongly suggests that  these e V. 
transcripts were relevant to the allergic immune response. The 
results  demonstrate  that  members  of all  human  V,  gene 
Table  1.  Distribution of Replacement and Silent Mutations in the 11,5 Regions of e  Transc@ts  from  three Patients with Atopic Dermatitis 
Total no.  Overall  CDR  FR  Total no.  Overall  CDR  FR 
Sequence  mutations  R/S  R/S  R/S  Sequence  mutations  R/S  R/S  R/S 
Pl-51  36  2.2  0.6  3.3  P2-51  23  1.1  1  1.1 
Pl-52  18  2.0  2.0  2.0  P2-52  20  1.2  3  1.0 
P1-53  9  8.0  i>3.0  5.0  P2-53  19  0.9  3  0.7 
P1-54  7  0.7  t>1.0  i>0.2  P2-54  21  1.0  1  1.1 
P1-55  23  2.8  5,0  2.4  P2-55  11  0.8  1  0.8 
P1-56  14  1.8  2.0  1.7  P2-56  32  1.6  2  1.5 
Pl-57  8  1.0  t>2.0  0.5  P2-57  6  1.0  -  1.0 
P1-58  17  2.4  1.5  3.0 
P3-9  6  5.0  i>4.0  1.0 
P3-60  14  1.8  2.5  1.3 
P3-63  36  2.6  2.5  2.7 
P3-69  8  1.7  ~>4.0  0.3 
For each E transcript, the total number of mutations (columns 2 and 7), the R/S ratio in the overall V.5 region (columns 3 and 8), the CDR region 
(columns 4 and 9) and the FR regions (columns 5 and 10) are depicted. 
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CDRI  120 
I 
GGA  TAC  AGC  TTT  ACC  AGC  TAC  TGG  ATC  GGC  TGG  GTG  CGC  CAG  ATG  CCC  GGG  AAA  GGC  CTG  GAG  TGG  AT(]  GGG  ATC  ATC 
....  T-  GAT  ---  T--  -CT  --t  ......................  G ...........................  a  --a  --- 
.......  A .....  A-  -C  ........... C ...................................  AC  --T  ......... 
............  G--  -C ........... C ................................................. 
...........  c  ....  C ..........  TC .....................  a  ........................... 
................  C .............................................  a  ........  a  T ..... 
................  a ............................................................. 
................  A .....................................................  T ....... 
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-A  ..................................  G ..............  G ....  c  ...... 
-A .........................  G ................................... 
-A-  A-t  .....................  G ................................... 
.............  T-  -CT  ..........  C ................................................. 
.............  T-  -CT  ..........  C ................................................. 
........  G  .......  A-  -C .......................................................... 
.......  AG  --C  -T-  G-T  --t  .......  C ........................  G  ....  c .................  c- 
GGA  TAC  AGC  TTT  ACC  AGC  TAC  TGG  AT(2  AGC  TGG  GTG  CGC  CAG  ATG  CCC  GGG  AAA  GGC  CTG  GAG  TGG  ATG  GGG  AGG  ATT 
.......  as  ..................................................................... 
....  T-  -C ....................  C ..............................  c  ...............  a-- 
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CDR2  210 
I 
TAT  CCT  GGT  GAC  TCT  GAT  ACC  AGA  TAC  AGC  CCG  TCC  TTC  CAA  GGC  CAG  GTC  ACC  AT(2  TCA  GCC  GAC  AAG  TCC  ATC  AGC 
--c  --g  ........................................  GC  ........ G  ...............  TC  .... 
....... A ........... T  .....................  g  --g  ................................. 
......................  A .................................  G  ...................  C  - 
--c  ...............  G ..................  C ..........  A .................  C ......... AT 
..........................  t  .....................  T--  T .......................  tc- 
..................................................................  G ........... 
...................  T ..............................................  S ........... 
.......  A .........  c  ...........  t  ..................  A ...........................  At 
.......  A ..........  G ..........  t  ...............................................  t 
.......  A ..........  G ..........  t  ...............................................  t 
.......  A .........  c  ...........  t  ..................  A ...........................  At 
.......  C ..................  t  --t  ...............................................  t 
.......  A .........  c  -T-  -A  ............  t  ....  G .............  T ..................  C-  -At: 
.............................................................  T ............  t  --- 
.............................................................................. 
..............  C  ....  TT  ........  t  ---  G ...........................  T ...............  t 
.......  C ....  GG-  --A  G .......  t  --t  .........  G ................  t  ....  T .....  C ........ A- 
GAT  CCT  AGT  GAC  TCT  TAT  ACC  AAC  TAC  AGC  CCG  TCC  TTC  CAG  GGC  CAC  GTC  ACC  AT(2  TCA  GCT  GAC  AAG  TCC  AT(2  AGC 
..................................................  A  ...........  c  ............. A- 
................  C-  --T  ......  t .................................................. 
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...............................................  C  ...............  CAT 
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CDR3 
GTC  GCA  CCA  GCC 
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GAC  TAC  GGT  GAC 
GAC  TAC  GGT  GAC 
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AGG  GGG  TCG  GGG 
AGG  GGG  TCG  GGG 
AGG  GGG  TCG  GGG 
GGC  CTT  CAT  GGG 
GGT  GAC  AGC  AGC 
GGA  ATG  GAA  TAT 
GCC  GAT  AAT  TTT 
CAT  CGA  GGT  GGG 
CGG  AGA  AAT  GGC 
CAA  ATG  TAT  AGC 
GGG  TAT  TGT  AGT 
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CDR3 
AAA  GTG  CAC  GGC  GAC 
GCT  ATT  ATC  TT 
TTG  GTC  TAC  GGA  ATC  TGG  AC 
GCT  CTC  GAG  ATG  GGC 
CTC  CTA  ATG 
TAC  CAA  TCC  ACG  GGG  GGC 
TAC  CAA  TCC  ACG  GGG  GGC 
ACT  TAT  TAT  AGT  GG 
ACT  TAT  TAT  ACT  GG 
ACT  TAT  TAT  ACT  GG 
ACT  TAT  TAT  ACT  GO 
ACC  TCC  TTC  TCA  AGC  TG 
AGA  TAC  TTC  CGT  GAT  CCC 
TAT  TAT  GGT  TCG 
GAC 
ACC  AAC  TAC 
CAC  AGT  TCC  GCT 
AAC  TCG 
GGT  GGT  ACC  TGC 
GGG  AGT  TCT  GAC  TAC  TAC  TAT  TAC 
GGG  TGG  TAT  TAT  CAG 
TAT  TCC  GAA  GCT  AAA  TCG  GGG 
GCT  TTT  GAT  GTC  TGG  GGC  CAA  GGG  ACA  ATG 
TAC  .....  C  TA  .........  G  --C  --C  C-- 
......  C  TT  .........  G  --A  --C  C-- 
....  C  TA  .........  G  --A  --C  C-- 
.....  C  TA  .........  G  --A  --C  C-- 
--C  TA  .........  G  --A  --C  C-- 
--C  --C  CC  .........  G  .....  C  T-- 
--C  --C  CC  .........  G  .....  C  T-- 
.......  AC  .................... 
.......  A .................... 
.......  A .................... 
.......  A .................... 
G  --C  ---  T .........  GG  --A  --C  C-- 
.....  C  A .................... 
TAC  A-G  --C  .........  A .......  C  -C- 
TGG  --C  C-A  A ..........  G  --A  --C  C-- 
GAG  TAC  --C  C-A  ...........  G  --C  --C  C-T 
-G-  A-G  ....................  C  -C- 
--C  TA  .........  G  --A  --C  C-A 
.....  C  TA  .........  G  --A  --C  C-- 
PI-51 
PI-52 
PI-53 
PI-55 
PI-56 
PI-54 
PI-57 
P2-51 
P2  -52 
P2  -53 
P2  -54 
P2  -55 
P2  -56 
P3-69 
P3  -9 
P3  -60 
P3  -63 
P2  -57 
PI-58 
---Cs 
OTC  ACC  GTC  TCT  TCA  GCC  TCC 
...........  C  --C  ......  JH4 
...........  C  .........  JH4 
...........  C  .........  JH4 
...........  C  --C  ......  JH4 
...........  C  .........  JH4 
...........  C  --G  ......  JH5 
...........  C  --G  ......  JH5 
.....................  JH3 
.....................  JH3 
.....................  JH3 
.....................  JH3 
.........  C-C  .........  JH5 
....  T .......  G ........  JH3 
...........  C  .........  JH6 
....  T ......  C  .........  JH4 
...........  C  .........  JHI 
...........  A  C ........  JH4 
C ..........  C  .........  JH5 
...........  C  .........  JH4 
Figure  1.  Nucleotide sequences  of e V.5 transcripts from atopic dermatitis patients  P1, P2, and P3. Nucleotide sequences are compared to the rear- 
ranged VHS-1R1 and VH5-1R2 genes that represent the two functional VN5 genes in germline configuration  (1". Logtenbe~g,  unpublished  data). The 
nucleotide sequences  of the corresponding germline VH5 gene segments of patients Pl, P2, and P3 were 100%  identical,  e~..ept for a single difference 
at position 42 in one of the alleles of patient P3 (*  and g). (Dashes) Nuclentide identity. The Js gene segments are aligned with the germline JK3 
gene (35).  Upper and lower case letters refer to R  and S mutations,  respectively. 
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5-2RIVH5 
PI-51 
PI-52 
P1-53 
P1-55 
P1-56 
PI-58 
P1-54 
P1-57 
P2-51 
P2-52 
P2-53 
P2-54 
P2-55 
P2-56 
P2-57 
P3-  60 
P3-  63 
P3-  69 
P3- 9 
Figure  2. 
CDRI  CDR2  CDR3  JH3  CE 
EVQLVQSGAEVKKPGESLK  I  SCKGSGY  SFTSYWIGWVRQMPGKGLEWMG  I  Iy  PGDSDTRy  S PSFQGQVT  I  SADKS  I  STAY  LQWS  S  LKAS  DTAMYYCAR  AFDVWGQGTMVTVS  S 
..................  R ...............  S ..............  R-D-S--Y-N  .......  H ............................... 
........  P-MRR--Q  ......  RS--FD-ST  ........  R ..........................  R--M  .....  S-A .....  T ........  I  -F- -  ~  KVAPAKVHGD  Y--Y  .....  L .....  ASTQ 
..................  Q ........  N-NT---A  ...........  YI .....  D---I  ..........................  G ........  F .... LKG~SHFL  --F ............... 
.............................  AT---A  .......................  K ..........  M ......  T ......  T ....  P  .........  QGRVRLATE  SGL  -Y ............... 
G---E  .................  N .......  T---S  ......................  A .....  S---I  .....  Q--N-V  .......  E .....  T- F- - -QLVPDALEMG  --Y ............... 
....................  T- -A ......  T ..................  F .................  FS ..............  N--T  .......  F- -  -RDDDQLLM  -Y ............... 
..................  R---Q---FT  ......  T ..............  R-D-S--HIN  .......  H ...........  V .... G--A  .......  F- - -VGYCSGGTCYSEAKSG  --Y ............... 
..............................  N ..........................................  E ..............  T .........  RDYGDYQSTGG  - -P ............... 
..............................  N .................  V ........  I  ...............  E ........................  RDYGDYQSTGG  - -  P ............... 
........  ED ................  F--  "N  ...........  E .... V .....  D .............  I  ........  N .......  N .....  S .....  T- PRGSGTYYSG  --T ............... 
........  E ...........  T-- -P-F-  - -N ................  V .....  D- -  -A ...................  S ........  R- --S .......  PRG SGTYYTG  - -T ............... 
........  E .................  F---N  ...........  E .... V .....  D---A  ...................  S  ............  S  .......  PRGSGTYYTG  --I ............... 
........  ED ................  F---N  ...........  E .... V .....  D .............  I  ........  N .......  N .....  S .......  PRGSGTYYSG  --I ............... 
..............................  N ........  V .............  A ................................  R .....  I  .....  HGFHGTSFSSW  --F--R--L---P  ..... 
.......................  A--  -T--NN  .......  V .............  D- -- IK .....  R ....  F .....  TN-S--H-N--R  .... GIFF-  -  -LGDSSRYFRDP  -- I  .......  I  ....... 
..................  R ...............  $ ..............  R-D-S--Y-N  .......  HI ........  N ...............  I  .....  HQMYSNS  -Y .....  LL ........ 
-E ....................  Q ....  R- -NS .........................  I  ....  A ........  V ..........................  THRGGTNY  EY-Q  ......  L ......... 
---Q  ...................  A---K-IG---A  .........  P .....  T--A-GEA  ......  E ......  V-T--N--F-H--T  .......  T- FRV-  HRRNGH  S  SAGWYYQ  GM .......  T ....  P  .... 
.............................  IT---A  ....................................  V ....................  T .....  HGMEYYYGSGSSDYYYY  YM ....  K--T  ......... 
.............................  IT---A  .........................................................  I  .....  HADNFD  W-QI  .....  L-I ....... 
Deduced amino acid sequences  of e V.5  transcripts.  Single-letter amino acid code is used. (Dashes) Identity of amino acid residue. 
families tested (V.3-V.6) may be utilized in the IgE response 
in atopic dermatitis patients. In PCR experiments,  we noted 
that the small V.5 gene family, consisting of two functional 
members, was abundantly expressed in e transcripts from all 
three patients,  whereas for example V.6,  a family of com- 
parable size, was not detectable in two patients,  and gener- 
ated a scarcely detectable PCR fragment in the third patient. 
Nucleotide sequence analysis of the V.5 genes present in 
the genome of the atopic dermatitis  patients permitted the 
unequivocal assignment of somatic mutations in the e V.5 
transcripts.  In 19 transcripts analyzed,  we detected  a total 
of 328 nucleotide differences (range 5-36 per V. segment) 
with the patient's own germline V.5 genes, including both 
S and R mutations. Based on a PCR-related  error frequency 
of <1/1,200, virtually all nucleotide differences represent so- 
matic mutations acquired during in vivo growth and differen- 
tiation of the corresponding B cells.  The distribution and 
types of mutations in the V regions of a B cell clone have 
been suggested to reflect the nature of the selective  forces 
causing its expansion (14,  15).  In the absence of selection 
and under the restraint of preserving the Ig molecule's struc- 
ture, R/S ratios have been estimated  to be 2.9 in the CDR 
and 1.5 in the FR regions (13). K/S ratios in the CDK regions 
that are substantially  higher than 2.9 have been interpreted 
emmh R 
~~T  EFNVDS 
NS 
Figure  3.  Genealogical  tree ofclonaUy rehted transcripts from patient 
P2. This tree was constructed to require the fewest independent parallel 
replacements. Single-letter amino add code is used to denote R mutations. 
to reflect a process of positive selection by antigen. The R/S 
ratios in the CDR and FK regions of the e V.5 transcripts 
do not exhibit a consistent pattern (Table 1). In fact, all com- 
binations of high and low R/S ratios in FK regions with 
high and low K/S ratios in CDR regions occur  (Table 1). 
Although this appears unusual for an antigen-driven  selec- 
tion process, several notions argue in favor of a role for an- 
tigen. Activation of the somatic hypermutation mechanism 
is associated with antigen stimulation and does not occur 
in polyclonally stimulated B cells (16, 17). Moreover, the al- 
lergen specificity  of the IgE antibodies  in the sera of these 
patients suggests an important role for allergen. Finally, the 
occurrence of clonally related B cells, as observed in two out 
of three patients, is characteristic for an antigen-driven  selec- 
PI-52 
DLR3 
PI-54 
PI-57 
D~I/4 
PI-55 
DLR4 
PI-56 
DLR4 
PI-58 
DLR2 
P2-51 
P2-52 
P2-53 
P2-54 
XP'I 
CTG  AAGGGGAAAATAG  CTATTTTCTT 
AGCATA-TGT-  -T-GTG  - -T ......  CC 
CGCGACTACGGTGACTACCAATCCACGC43GGGC 
................................. 
T ......  A--A  ..... 
CAATTAG  TTCCAGATGCTCTCGAG  ATGGGC 
AGGATATTGT-G  ....  A ....  C ....  ATGCC 
CGTGATGACGACCAGCTCCTAATG 
AGGATATTGTAGTAGT  .......  G - - -TGCC 
GTCGGG  TATTGTAGTGG  TGGTACCTG  C TATTC  CGAAG  CTAAATCGGGG 
A--A  ................  G ......  C--- 
C CG AGGGGGTCGGGGACTTATTATAG  TGG 
.........................  C-~- 
.........................  C--- 
............................. 
GTATTACTAT-  -T .......  G ........  A 
P2-56 
DNI 
P2-57 
DN4 
P3-9 
XPI 
P3-60 
DLR3 
P3-63 
DLR4 
DAI/4 
P3-69 
XP'I 
Figure  4. 
CTCGGTGACAGCAGCAGATACTTCCGTGATCCC 
GGGTATAG  .......  T-G-  - - 
C ATCAAATGTATAGC  AACTCG 
GA  ........  G ....  TCC 
CATGCCGATAA%TFAGAC 
GT-  -TA  .....  T-  - -GACTGGTTATTATAA 
ACACATCGAGGTGGGACCAACTAC 
AG  - -T-  -T-T  .....  TGATTG  - - -TTCC 
C ATCGGAG  AAATGG  CCACAGTTCCGCTGGG  TGGTATTATCAG 
AGGATATT-  -A-  - -G - -C - - - 
--A-T  .....  AA-TAC 
CATGG  AATGG  AATATTATTATGGTTCGGGG  AG TIL-"I~ ACTACTACTATTAC 
G .....  C ................  A-T-TA- 
Alignment  of nucleotide  sequences of D. gene segments uti- 
lized in e transcripts and reported germline D. elements. The D. regions 
of P1-51, P1-53, and P2-55 could not be reliably matched with published 
germline D. segments. (Dashes) Nucleotide identity. 
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the heterogeneous R/S patterns in e V.5 transcripts are con- 
ceivable. The FR regions,  especially FR3, may contribute 
to antigen binding, as has been argued on the basis of ex- 
perimental data and theoretical considerations (18-21). In this 
respect, it is important to realize that antigen determines the 
shape of the antigen-binding portion of V regions and that 
current concepts concerning R/S distributions  have largely 
been derived from analysis  involving immunization with hap- 
tenic groups. The antigen combining site of hapten-binding 
antibodies may differ profoundly  from that of  protein-binding 
antibodies. Examples of nonhaptenic immune responses  gener- 
ating high affinity antibodies with "aberrant" R/S mutations 
have been reported in the literature (22-24).  An alternative 
interpretation is an extension of a model proposed by Manser 
(25). It may be envisaged that initially, somatic mutations 
are efficiently selected by antigen resulting in affinity matu- 
ration  of the immune response.  In  case of recurrent or 
prolonged antigenic stimulation, the extent to which somatic 
mutations lead to higher binding affinity in an already sdected 
B call done becomes limited and finally saturated.  At this 
point, persistent antigenic stimulation may result in the ac- 
cumulation of "neutral" R and S mutations, i.e., mutations 
that do not affect the affinity or the structural integrity of 
the Ig molecule. Such mutations are not selected  for or against, 
and may shift the R/S ratio towards a pattern resembling 
random mutations. It may be envisaged that such a pattern 
of mutations of V regions is associated with antigens that 
chronically and/or recurrently stimulate the immune system, 
as is the case with allergens and perhaps particular  autoan- 
tigens (22). In the above scenario, mutations continue to occur 
in secondary and higher order immune responses as a result 
of repeated or chronic exposure to the same antigen. 
Four out of seven e V.5 sequences from patient P2 were 
donally related as judged by their junctional regions. This 
set of sequences contained,  in addition to many shared so- 
matic mutations,  at  least  three unique mutations.  These 
numbers represent a minimum estimate because somatic mu- 
tations in the DR and JR segments were not included in our 
analysis. We constructed a genealogical tree based on the 
premise that the most shared mutations were acquired early, 
and the least shared mutations were acquired late in the evo- 
lution of the done. Indeed, the general pattern of mutations 
appears to reflect the temporal order of somatic mutations 
acquired  during expansion  of the done (17, 26).  A  small 
number of shared mutations in the clonally related set of e 
transcripts likely arose as a result of parallel events (i.e., the 
A-*T at position 17 and the A--~G at position 127; Fig. 1). 
It has been previously reported that the V regions of mu- 
rine hybridomas secreting monodonal antihapten antibodies 
share  somatic  mutations,  even among  hybridomas  from 
different mice and generated in different laboratories (27, 28). 
In addition, shared mutations have been noted in hybridomas 
carrying "passenger" transgenes that are not functionally  ex- 
pressed (29, 30). Shared R mutations have been interpreted 
to reflect the influence of antigen sdection conferring prolifer- 
ative advantage to the B cell clone, whereas shared S muta- 
tions may mark positions that are especially  prone to somatic 
mutation, so-called hot spots (28, 31). In the collection of 
19 e V.5 transcripts, we found a remarkably high incidence 
of shared mutations, even among transcripts  derived from 
different  germline members of the V.5  gene family. The 
shared mutations were distributed over CDR and FR regions 
and included both S and R  mutations. In the current anal- 
)'sis, it can be excluded that these mutations represent artifacts 
introduced, for example, as a consequence of cell fusion or 
in vitro growth of hybridomas.  A high number of muta- 
tions in the collection of e V.5 transcripts  was also found 
in two V.5 expressed genes reported by Andris et al. (32). 
Thus, out of 17 mutations present in a V.5 gene encoding 
an anti-HIV antibody,  12 are also present in the same posi- 
tion in at least one but often multiple e VH5 transcripts, 
seven of which constitute identical substitutions (32). Simi- 
larly, the majority of mutations present in the V,5 genes en- 
coding an antiinsulin  autoantibody and an antirabies virus 
antiidiotypic  antibody also appear in multiple independent 
e  V.5  transcripts  (33). Thus,  the  seemingly unprobable 
event of isolating multiple parallel somatic alterations in V. 
transcripts from unrelated individuals and in antibodies with 
different specificities constitutes,  in fact, a frequently occur- 
ring phenomenon. 
The molecular basis for the high incidence of shared mu- 
tations remains to be elucidated. Based on thdr diversity,  mul- 
titude, and distribution pattern in the collection  of e V,5 
transcripts, it seems unlikely that a somatic gene conversion 
mechanism, even when considering multiple segmental ex- 
changes, is a major contributor (34). Rather,  the accumula- 
tion of point mutations, perhaps in combination with in- 
trinsic  sequence specificity of the somatic  hypermutation 
mechanism, constitutes the mechanism underlying shared mu- 
tations (30). In addition,  selection by antigen probably con- 
tributes to the occurrence of shared R mutations. Although 
we have not addressed the antigen specificity of the IgE anti- 
bodies encoded by these transcripts,  it seems unlikely that 
they all bind to the same epitope. 
We thank Dr. W. J.  Koers  for supplying us with blood samples of atopic dermatitis patients. 
This work was supported  by grant 328926 from Het Nederlands  Astma Fonds. Ton Logtenberg  is a fellow 
of the Royal Dutch Academy  of Arts and Sciences. 
105  van der Stoep et al, Address correspondence to Ton Logtenberg, Department of Immunology, University Hospital Utrecht, 
Heiddberglaan  100, 3508 GA Utrecht,  The Netherlands. 
Received for publication  10 August  1992 and in revised form  I4  October  1992. 
~ere/ices 
1.  Hanifin,  J.M. 1984. Atopic dermatitis.J. Allergy Clin. Immunot. 
73:211. 
2.  Sampson, H.A. 1989. Role of immediate hypersensitivity in 
the pathogenesis of atopic dermatitis. Allergy. 44:52. 
3.  P~ne,  J., F. Rousset, F. Bri~re, I. Chr6tien, J.Y. Bonnefoy,  H. 
Spits, T. Yokota, N. Arai, K. Arai, J. Banchereau, and J.E. 
de "Cries. 1988. IgE production by normal human lymphocytes 
is induced by interleukin 4 and suppressed by interferon 3' and 
c~ and prostagiandine E2. Proa Natl. Acad. Sci. USA. 85:6880. 
4.  Parronchi,  P., D. Macchia, M. Piccinni, P. Biswas, C, Simonelli, 
E. Maggi, M. Ricci, A.A. Ansari, and S. Romagnani. 1991. 
Allergen- and bacterial antigen-specific  T-cell clones established 
from atopic donors show a different  profile  of  cytokine produc- 
tion. Proc. Natl.  Acad. Sci. USA.  88:4538. 
5.  Wierenga, E.A., M. Snoek, H.M. Jansen, J.D. Bos, R.A.W. 
van Lier, and M.L. Kapsenberg. 1991. Human atopen-specific 
types 1 and 2 T helper cell clones. J, Immunol.  147:2942. 
6.  Hanifin,  J.M., and G. Rajka. 1980. Diagnostic  features  of atopic 
dermatitis. Acta Dermato..Venereol. Suppl. 92:44. 
7.  Ausubel, F.M., R. Brent, R.E. Kingston, D.D. Moore, J.G. 
Seidman,  J.A. Smith, and K. Struhl. 1988. Current Protocols 
in Molecular Biology. Vol. 1 and 2. Greene Publishing As- 
sociates and Wiley-Interscience, New York. 
8.  Higuchi, R. 1989. Rapid, efficient DNA extraction for cells 
or blood. Amplifications. 2:1. 
9.  Van Es, J.H., F.H.J. Gmelig Meyling, W.R.M. van de Akker, 
H. Aanstoot, R.H.W.M. Derksen, and T. Logtenberg. 1991. 
Somatic mutations in the variable  regions of  a human IgG anti- 
double-stranded DNA autoantibody suggest a role for antigen 
in the induction of systemic  lupus erythematosus.J. Ex  F Med. 
173:461. 
10.  Sanz, I., P. Kelly, C. Williams, S. Scholl, P. Tucker, and J.D. 
Capra. 1989. The smaller human Vs gene families  display re- 
markably little polymorphism. EMBO (Eur. Mol. Biol. Organ.) 
j. 8:3741. 
11.  Berman, J.E., S.J. Mellis, R. Pollock, C.L. Smith, H. Suh, 
B. Heinke, C. Kowal, U. Surti, L. Chess, C.R. Cantor, and 
F. Alt. 1988. Content and organization of the human Ig V. 
locus: definition of three new V. families and linkage to the 
Ig C. locus. EMBO (Eur. Mol. Biol. Organ.) J.  7:727. 
12.  Sanger, F., S. Nicklen, and A.R. Coulsen. 1977. DNA se- 
quencing with chain-terminating inhibitors. Proc. Natl. Acad. 
Sci. USA.  74:5463. 
13.  Shlomchik, M.J.,  A.H.  Aucoin, D.S. Pisetsky, and M.G. 
Weigert. 1987. Structure and function of anti-DNA autoanti- 
bodies derived from a single autoimmune mouse. Proc. Natl. 
Acad. Sci. USA.  84:9150. 
14.  Shlomchik,  M.J., D.A. Nemazee,  J. van Snick, and M. Weigert. 
1987. Variable  region sequences  of  murine IgM anti-IgG mono- 
clonal autoantibodies (rheumatoid factors). II. Comparison of 
hybridomas derived  by lipopolysaccharide  stimulation and sec- 
ondary protein immunization. J. Exit Med. 165:970. 
15.  Shlomchik,  M.J., A. Marshak-Rothstein,  C.B. Wolfowicz,  T.L. 
Rothstein, and M.G. Weigert. 1987. The role of clonal selec- 
tion and somatic mutation and autoimmunity. Nature (Lond.). 
328:805. 
16.  Manser, T., L.J. Wysocky, M.N. Margolies, and M.L. Gefter. 
1987. Evolution of antibody variable structure during the im- 
mune response. Immunol.  Rev. 96:141. 
17.  Rudikoff, S., M. Pawlita, J. Pumphrey, and M. HeUer. 1984. 
somatic diversification  of immunoglobulins. Proc. Natl. Acad. 
Sci. USA.  81:2162. 
18.  Alzari, P.M., S. Spinelli, R.A. Mariuzza, G. Boulot,  K.J. 
Poljak, J.M. Jarvis, and C. Milstein. 1990. Three-dimensional 
structure determination  of an anti-2-phenyloxazolone  antibody: 
the role of somatic mutation and heavy/light chain pairing 
in the maturation of an immune response. EMBO (Eur. Mol. 
Biol. Organ.) J.  9:3807. 
19.  Amit, A.G., R.A. Mariuzza, S.E.V. Phillips, and R.J, Poljak. 
1986. Three-dimensional  structure of an antigen-antibody  com- 
plex at 2.8 J~ resolution. Science (Wash. DC).  233:747. 
20.  Schroeder,  H.W.,Jr, J.L. Hillson, and R.M. Perlmutter. 1989. 
Structure and evolution of mammalian V. families. Int. Ira. 
munol. 2:41. 
21.  Rose,  D.R., R.K. Strong, M.N. Margolies, M.L. Gefter, and 
G.A. Petsko. 1990. Crystal structure of the antigen-binding 
fragment of the murine anti-arsonate monoclonal antibody 
36-71 at 2.9-A resolution. Pro~ Natl./,cad. Sci. USA. 87:338. 
22.  Randen, I., D. Brown, K.M. Thompson, N. Hughes-Jones, 
V. Pascual, K. Victor, J.D. Capra, O. Forre, and J.B. Natvig. 
1992. Clonally  related  IgM rheumatoid factors  undergo affinity 
maturation  in the  rheumatoid  synovial tissue. J.  Imraunol. 
148:3296. 
23.  Adderson, E.E., P.G. Shackelford, A. Qninn, and W.L. Car- 
roll. 1991. Restricted Ig H chain V gene usage in the human 
antibody response to Haemophilus influenza type b capsular 
polysaccharide.  J. Immunol.  147:1667. 
24.  Clarke, S., R. Rickert, M.K. Wloch, L. Standt, W. Gerhard, 
and M. Weigert. 1990. The BALB/c secondary response to 
the  sb  site of influenza virus hemagglutinin. J.  Imraunol. 
145:2286. 
25.  Manser, T. 1989. Evolution of antibody structure during the 
immune response.  J. Ex  F  Med. 170:1211. 
26.  Mckean, D., K. Huppi, M. Bell, L. Staudt, W. Gerhard, and 
M. Weigert. 1984. Generation of  antibody diversity  in the im- 
mune response of BALB/c mice to influenza virus hemaglu- 
tinin. Pro~ Natl.  A_cad. Sci. USA.  81:3180. 
27.  Wysocky, L.J., M.L. Gefter, and M.N. Margolies. 1990. Par- 
alld evolution  of antibody  variable regions  by somatic  processes: 
consecutive shared somatic alterations in  the V. genes ex- 
pressed by independently generated hybridomas  apparently ac- 
quired by point mutation and selection rather than by gene 
conversion, f  Exit Med. 172:315. 
28.  Berek, C,, and C. Milstein. 1987. Mutation drift and reper- 
toire shift in the maturation of the immune response. Imraunol. 
Reg 96:23. 
29.  Sharpe, M.J., C. Milstein, J.M. Jarvis, and M.S. Neuberger. 
1991. Somatic hypermutation of immunoglobulin K  may de- 
106  Molecular  Characteristics of e Va Regions in Atopic Dermatitis pend on sequences 3' of C, and occurs on passenger trans- 
genes. EMBO (Eur. Mol. Biol. Organ.)  J.  10:2139. 
30.  Hackett, J., Jr., B.J. Rogerson,  R.L. O'Brien, and U. Storb. 
1990. Analysis of somatic mutations  in K transgenes, f  Ex  F 
Med. 172:131. 
31.  Levy,  S., E. Mendel, S. Kon, Z. Avnur, and R. Levy. 1988. 
Mutational hot spots in Ig V region genes of human follicular 
lymphomas. J. Exl~ Med. 168:475. 
32.  An&is, J.S., S. Johnson, S. ZoUa-Pazner,  andJ.D. Capra. 1991. 
Molecular  characterization  of five human  anti-human  im- 
munodeficiency virus type 1 antibody heavy chains reveals ex- 
tensive somatic mutation typical of an antigen-driven immune 
response. Pro~ Natl. Acad. Sci. USA.  88:7783. 
33.  Sanz, I., P. Casali, J.W. Thomas, A.L. Notldns, andJ.D. Capra. 
1989. Nucleotide sequences of eight human natural autoanti- 
body VH regions reveals apparent restricted use of VH families. 
f  Immunol. 142:4054. 
34,  Wysocki, L.J. 1989. Gene conversion and the generation  of 
antibody diversity. Annu. Rev. Biochem. 58:509. 
35.  Kabat, E.A., T.T. Wu, M. Reid-Miller, H.M. Perry, and K.S. 
Gottesman. 1987. Sequences  of  Proteins of Immunological In- 
terest. 4th edition. U.S. Government Printing Office, Bethesda, 
MD. 674 pp. 
107  van der Stoep et al. 